AbbVie stock slips as traders watch Epkinly data and the next earnings clock
AbbVie shares fell 0.4% to $213.53 in early afternoon trading after phase III results for Epkinly showed a progression-free survival benefit but no statistically significant overall survival in lymphoma patients. The stock moved between $210.00 and $214.23 as investors looked ahead to the Feb. 4 earnings report and 2026 outlook.